Blog

FDA Delays UDI Requirements for Low-Risk Devices

The US Food and Drug Administration (FDA) on Friday, June 2, 2017 notified medical device labelers that it is extending the compliance dates for certain unique device identifier (UDI) requirements for Class I and unclassified devices.

New blood biomarker could enhance early detection of heart attack risk

When it comes to predicting who is at risk of suffering a heart attack or other major cardiac events, physicians have long relied on detecting high levels of C-reactive protein (CRP), an inflammatory biomarker.  However, new research suggests CRP may not be the only game in town.

Researchers question Gottlieb ties, balk against NIH cuts

A new survey of U.S. scientists, FDA researchers and biomedical clinicians has found that most are concerned over FDA Commissioner nominee Scott Gottlieb’s long list of ties to biopharmas, with the majority also believing that proposed cuts to the National Institutes of Health (NIH) would hurt drug discovery.

Autism: Beware of Potentially Dangerous Therapies and Products

One thing that is important to know about autism up front:  There is no cure for autism.  So, products or treatments claiming to “cure” autism do not work as claimed.  The same is true of many products claiming to “treat” autism or autism-related symptoms. Some may carry significant health risks.

FDA allows marketing of first direct-to-consumer tests that provide genetic risk information for certain conditions

The U.S. Food and Drug Administration in April allowed marketing of 23andMe Personal Genome Service Genetic Health Risk (GHR) tests for 10 diseases or conditions.  These are the first direct-to-consumer (DTC) tests authorized by the FDA that provide information on an individual’s genetic predisposition to certain medical diseases or conditions, which may help to make decisions about lifestyle choices or to inform discussions with a health care professional.